The Retina Group of New York announced the availability of Eylea (aflibercept), the latest in a series of anti-VEGF medications for all patients with the wet (neovascular) form of macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older. The safety and effectiveness of Eylea was evaluated in two clinical trials involving 2,412 adult patients. The studies showed that Eylea was as effective as Lucentis in maintaining most vision in 95% of patients and improved vision in over 30% of patients. The Food and Drug Administration approved Eylea on November 18, 2011 and it is now available to patients for treatment by the Retina Group of New York in their Hicksville and Hauppauge offices.
(PRWeb November 28, 2011)
